GNQ Insilico
- Company typePrivate
- Founded-
- HeadquartersPleasanton, United States
- Headcount—
- GTM typeB2B
- OfferingSoftware
GNQ Insilico firmographics
Firmographics- Name
- GNQ Insilico
- Legal name
- GNQ Insilico Inc.
- Website
- https://gnqin.com
- Company type
- Private
- Operating status
- Operating
- Ownership category
- akta.pro rank
GNQ Insilico industry classification
Industry- Product category
- AI-Driven Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where GNQ Insilico is headquartered
LocationHeadquarters
- HQ city
- Pleasanton
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
GNQ Insilico business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Licensing: Licensing proprietary AI-driven precision medicine platforms, insights, and technologies to pharmaceutical companies, research institutions, and healthcare organizations. The three-year $96 million agreement represents this licensing model.
- Technology Partnership Revenue: Revenue generated through strategic collaborations with technology providers and life sciences companies, including consulting integration services and hybrid cloud infrastructure partnerships.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
GNQ Insilico product offering
Product offeringCore offering
GNQ Insilico develops and licenses an AI- and quantum-enabled precision medicine platform that integrates genomics, causal AI, and quantum molecular simulation to accelerate drug discovery and development and to support personalized clinical decision-making. Core deliverables include the Drug Assessment Platform and the AI-Driven Drug Assessment, Simulation, and Digital Twin Platform, sold via enterprise platform licensing to pharmaceutical companies, biotech firms, healthcare providers, and research institutions.
Product overview
GNQ Insilico operates as a TechBio company offering a unified precision medicine platform built on the integration of genomics, AI, and quantum computing. The core product portfolio includes the Drug Assessment Platform and the AI-Driven Drug Assessment, Simulation, and Digital Twin Platform. The Drug Assessment Platform provides AI and quantum-enhanced modeling for accelerating drug development, improving safety, and informing regulatory strategies. The AI-Driven Drug Assessment, Simulation, and Digital Twin Platform combines causal AI frameworks with quantum molecular simulation capabilities, leveraging a dataset derived from over 15,000 case studies to support genomic stratification, pharmacokinetic simulation, and personalized treatment decisions. Together, these offerings enable pharmaceutical companies, research institutions, and healthcare providers to improve drug development efficiency and clinical outcomes.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Assessment Platform AI- and quantum-enhanced platform for drug development assessment that accelerates development timelines, improves safety predictions, and informs regulatory strategies through mechanistic modeling and simulation. Designed for pharmaceutical companies and biotech firms.
- AI-Driven Drug Assessment, Simulation, and Digital Twin Platform Integrated platform combining causal AI drug assessment, quantum molecular simulation, and digital twin technologies to help life sciences companies and healthcare providers improve drug development and personalized clinical decision-making. Powered by a dataset of 15,000+ case studies.
Quantifiable outcome
- Platform aims to address high clinical trial failure rates
- +1 more outcomes
Companies that use GNQ Insilico
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
GNQ Insilico technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
GNQ Insilico partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- IBMflagshipGNQ Insilico announced a collaboration with IBM to deliver AI-driven drug assessment, simulation, and digital twin platforms to healthcare and life sciences organizations. The collaboration integrates GNQ's causal AI frameworks with IBM's consulting expertise and hybrid cloud infrastructure. This partnership has already generated commercial momentum through a three-year, $96 million agreement with a physician-led comprehensive health program operating across North America.
- MindLabcoreGNQ Insilico announced a strategic partnership with MindLab, an award-winning pharmaceutical company, to deploy its Drug Assessment Platform for developing MindLab's pain management therapy MLB-001. The collaboration focuses on optimizing dosing, clinical trial design, and safety predictions through AI and quantum-enhanced modeling.
- Clemson University Biomedical Engineering Innovation CampuscoreGNQ Insilico will establish initial lab operations at the Clemson University Biomedical Engineering Innovation Campus as part of its relocation from California to Greenville, South Carolina.
- Prisma HealthcoreGNQ Insilico will be embedded in an environment anchored by Prisma Health at the Clemson University Biomedical Engineering Innovation Campus location in Greenville.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
GNQ Insilico competitors and assessment
Company assessmentDirect peers
- XtalPi: AI- and quantum-physics-driven drug discovery company combining computational chemistry with robotic experimentation. One of the closest peers to GNQ given the explicit AI+quantum combination and enterprise pharma customers.
- Atomwise: AI small-molecule drug design company using deep learning to predict binding and optimize leads. Comparable to GNQ's molecular simulation and drug assessment angle, with multiple pharma collaborations and a strong enterprise focus.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with ML to identify novel therapeutics. Most directly comparable to GNQ in the AI-for-drug-discovery category, with a much larger disclosed pipeline and a more mature platform.
- Schrödinger: Public computational chemistry and molecular simulation company offering a physics-based software platform for drug discovery. Highly comparable to GNQ's drug assessment and molecular simulation capabilities, with established enterprise pharma customers.
- Insitro: Private ML-driven drug discovery company combining data generation and predictive models to develop therapeutics. Comparable to GNQ in target identification and predictive modeling, with deeper capital backing and biopharma partnerships.
- Exscientia: AI-driven precision medicine and drug design company that built end-to-end AI capabilities for small molecule discovery. Direct competitor to GNQ in AI drug design, with disclosed pharma partnerships and a public listing history.
- Insilico Medicine: AI-driven drug discovery company combining generative AI, target identification, and clinical prediction. Closely comparable to GNQ in applying AI across the drug discovery pipeline, with a broader clinical pipeline and more disclosed programs.
- Isomorphic Labs: Alphabet-owned AI drug discovery spinout applying deep learning to biology and chemistry. Highly comparable to GNQ in digital twin and AI-driven drug assessment ambitions, with significantly greater capital and compute resources.
Emerging players
- Cradle Bio: ML platform for protein and biologics design, focused on generative models for novel sequences. Adjacent to GNQ in applying AI/ML to drug discovery, with overlap in customer base and platform licensing GTM.
Broad incumbents
- Tempus AI: Public AI-driven precision medicine company focused on clinical decision support, multi-omics data, and diagnostics. Comparable to GNQ in the multi-omics/precision medicine layer, but with a much broader portfolio spanning clinical workflows, diagnostics, and pharma services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
GNQ Insilico social profiles
Digital presenceGNQ Insilico financial estimates
Financial estimateRevenue estimate
Valuation estimate
GNQ Insilico leadership team
Management profileNumber of profiles
GNQ Insilico funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GNQ Insilico M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GNQ Insilico
What does GNQ Insilico do?
GNQ Insilico develops and licenses an AI- and quantum-enabled precision medicine platform that integrates genomics, causal AI, and quantum molecular simulation to accelerate drug discovery and development and to support personalized clinical decision-making. Core deliverables include the Drug Assessment Platform and the AI-Driven Drug Assessment, Simulation, and Digital Twin Platform, sold via enterprise platform licensing to pharmaceutical companies, biotech firms, healthcare providers, and research institutions.
Is GNQ Insilico a public or private company?
GNQ Insilico is a private company. It is classified as unknown and is currently operating.
When was GNQ Insilico founded?
GNQ Insilico was founded in -1.
Where is GNQ Insilico based?
GNQ Insilico is headquartered in Pleasanton, United States, in the North America region.
How does GNQ Insilico make money?
Two revenue lines are on record. Platform Licensing is the primary driver. The others are technology Partnership Revenue.
Who are GNQ Insilico's main competitors?
Direct peers on record are XtalPi, Atomwise, Recursion Pharmaceuticals, Schrödinger, Insitro, Exscientia, Insilico Medicine and Isomorphic Labs. Cradle Bio is listed as an emerging player. Tempus AI is listed as a broad incumbent.
Does GNQ Insilico have an API?
No public API is recorded for GNQ Insilico.
What industry is GNQ Insilico in?
GNQ Insilico's product category is AI-Driven Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 541714 and its SIC code is 7373.